Sign in Subscribe
Cancer research

Promising Treatment Option for Extensive-Stage Small Cell Lung Cancer Liver Metastases

Strategic Insights

— 1 min read

Research findings presented in a new report from the Shanxi Province Cancer Hospital in Taiyuan, People's Republic of China, indicate that the combination of serplulimab with platinum-based chemotherapy yields promising results in treating extensive-stage small cell lung cancer (ES-SCLC) liver metastases. The study involved 30 patients with ES-SCLC liver metastases who received the combination therapy as a first-line treatment. The results showed an objective response rate (ORR) of 63.3% and a disease control rate (DCR) of 83.3%. The median progression-free survival (PFS) was 5.9 months, and the median overall survival (OS) was 9.1 months.

Key Takeaways:

  • The combination of serplulimab with platinum-based chemotherapy demonstrated promising effectiveness in treating ES-SCLC liver metastases, with an ORR of 63.3% and a DCR of 83.3%.
  • The study analyzed the associations between prognosis and the depth of remission of primary lung lesions and liver metastases, finding that patients with a depth of remission of primary lung lesions 30% experienced significantly longer median PFS and OS.
  • The treatment regimen resulted in manageable safety profiles, making it an attractive option for the first-line management of ES-SCLC liver metastases.
  • The study included a total of 30 patients with ES-SCLC liver metastases, with a median age of 67 years.
  • The researchers concluded that the combination of serplulimab with platinum-based chemotherapy may provide an effective treatment option for ES-SCLC liver metastases.

Statistics:

  • Objective response rate (ORR): 63.3% (95% CI, 43.9-80.1)
  • Disease control rate (DCR): 83.3% (95% CI, 65.3-94.4)
  • Median progression-free survival (PFS): 5.9 months (95% CI, 4.3-8.1)
  • Median overall survival (OS): 9.1 months (95% CI, 6.1-16.2)
  • Depth of remission of primary lung lesions 30%: median PFS (8.1 months [95% CI, 6.4-NE] vs. 3.9 months [95% CI, 3.2-6.3], HR:0.28, 95%CI: 0.12-0.65) and median OS (16.2 months [95% CI, 9.1-NE] vs. 5.5 months [95% CI, 3.7-13.6], HR: 0.31, 95%CI: 0.12-0.81)

Sources:

  • Effectiveness and safety of serplulimab plus platinum-based chemotherapy in first-line treatment of extensive-stage small cell lung cancer liver metastases: a retrospective cohort study. Frontiers in Oncology, 2025;15:1645692.

Read more